サンプル依頼リスト カート
  • English
  • Korean
表紙：分子診断薬の世界市場 (2021-2031年)：製品・検査ロケーション・用途・技術・エンドユーザー・地域別
市場調査レポート
商品コード
1036776

分子診断薬の世界市場 (2021-2031年)：製品・検査ロケーション・用途・技術・エンドユーザー・地域別

Molecular Diagnostics Market - A Global and Regional Analysis: Focus on Product, Testing Location, Application, Technology, and End User - Analysis and Forecast, 2021-2031
出版日: | 発行: BIS Research Inc. | ページ情報: 英文 468 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円
分子診断薬の世界市場 (2021-2031年)：製品・検査ロケーション・用途・技術・エンドユーザー・地域別
出版日: 2021年11月12日
発行: BIS Research Inc.
ページ情報: 英文 468 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の分子診断薬の市場規模は予測期間中7.38%のCAGRで推移し、2020年の109億1,460万米ドルから、2031年には242億2,800万米ドルの規模に成長すると予測されています。

感染症やさまざまな種類の癌の有病率の急増、個別化医療に対する認識および受容性の世界的な拡大、R&Dへの大規模な資金提供などの要因が同市場の成長を推進しています。一方で、不確実な償還シナリオ、高度複雑検査センターの不足、新しい分子診断テストの承認を遅らせる複雑な規制の枠組みなどが、市場のさらなる成長を妨げています。

当レポートでは、世界の分子診断薬の市場を調査し、市場の定義と概要、市場影響因子の分析、技術・特許の動向、市場規模の推移・予測、製品・検査ロケーション・技術・用途・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 市場

  • 製品の定義
  • 市場概要
  • 歴史的展望
  • 重要技術
  • 分子診断の分類
  • 世界のフットプリント
  • 世界の分子診断市場規模・予測：現実的・楽観的・保守的成長シナリオ
  • 将来の可能性
  • 市場力学
    • 影響分析
    • 市場推進要因
    • 市場抑制要因
    • 市場機会
  • COVID-19の影響
  • 競合情勢
  • 産業考察
  • 特許分析

第2章 製品

  • システム
  • キット・消耗品
  • ソフトウェア・その他の製品

第3章 検査ロケーション

  • ラボ検査
  • POC (ポイントオブケ) 検査

第4章 技術

  • ポリメラーゼ連鎖反応 (PCR)
  • 次世代シーケンス
  • 等温核酸増幅技術 (INAAT)
  • マイクロアレイ
  • In-Situハイブリダイゼーション (ISH)
  • 免疫組織化学 (IHC)
  • その他

第5章 用途

  • コア分子診断
  • 生殖ジェネティクス
  • コンパニオン診断 (CDx)
  • リキッドバイオプシー
  • その他

第6章 エンドユーザー

  • 病院
  • 診断センター
  • 外来診療所/一般開業医
  • 研究機関
  • その他

第7章 地域

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • その他の地域

第8章 企業プロファイル

  • Abbott
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company(BD)
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Danaher
  • F. Hoffmann-La Roche Ltd
  • Guardant Health
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • ICON plc
  • LungLife AI, Inc.
  • QIAGEN
  • QuantuMDx Group Ltd.
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc.
図表

List of Figures

  • Figure 1: Annual NIH Funding in Human Genomics Research, $Billion, FY2013-FY2019
  • Figure 2: Global Molecular Diagnostics Market (Realistic and Optimistic Scenario), $Million, 2020-2031
  • Figure 3: Global Molecular Diagnostics Market, Market Dynamics
  • Figure 4: Share of Key Market Strategies and Developments, January 2017-September 2021
  • Figure 5: Global Molecular Diagnostics Market Snapshot, $Million, 2020-2031
  • Figure 6: Global Molecular Diagnostics Market (by Product), $Million, 2020 Vs. 2031
  • Figure 7: Global Molecular Diagnostics Market (by Technology), $Million, 2020 Vs. 2031
  • Figure 8: Global Molecular Diagnostics Market (by Application), $Million, 2020 Vs. 2031
  • Figure 9: Global Molecular Diagnostics Market (by End User), $Million, 2020 Vs. 2031
  • Figure 10: Global Molecular Diagnostics Market (by Region), $Million, 2020 Vs. 2031
  • Figure 11: Global Molecular Diagnostics Market Research Methodology
  • Figure 12: Global Molecular Diagnostics Market: Segmentation
  • Figure 13: Figure 1.1: Role of Diagnostics in Healthcare
  • Figure 14: Evolution of Molecular Diagnostics
  • Figure 15: Classification of Molecular Diagnostics
  • Figure 16: Global Molecular Diagnostics (MDx) Market, $Million, 2020-2031
  • Figure 17: Global Molecular Diagnostics Market Size and Growth Potential (Realistic Scenario), $Million, 2020-2031
  • Figure 18: Global Molecular Diagnostics Market Size and Growth Potential (Conservative Scenario), $Million, 2020-2031
  • Figure 19: Global Molecular Diagnostics Market Size and Growth Potential (Optimistic Scenario), $Million, 2020-2031
  • Figure 20: Global Molecular Diagnostics Market - Market Dynamics
  • Figure 21: Distribution of Cases and Deaths by World Regions and Cancer Types
  • Figure 22: Personalized Care for Cancer Patients
  • Figure 23: Impact of COVID-19 on Global Molecular Diagnostics Market
  • Figure 24: Share of Key Developments and Strategies, January 2017-September 2021
  • Figure 25: Share of Acquisitions (by Company), January 2017-September 2021
  • Figure 26: Share of Synergistic Activities (by Company), January 2017-September 2021
  • Figure 27: Share of Product Launches and Upgradations (by Company), January 2017-September 2021
  • Figure 28: Share of Business Expansion (by Company), July 2017-August 2021
  • Figure 29: Market Share Analysis for Global Molecular Diagnostics Market, $Million, 2019 and 2020
  • Figure 30: Growth Share Analysis of Global Molecular Diagnostics Market (by Technology), 2020-2031
  • Figure 31: Responsibilities of the National Medical Products Administration (NMPA)
  • Figure 32: Year-Wise Analysis of Patents Related to Molecular Diagnostics, January 2019- October 2021
  • Figure 33: Country-Wise Analysis (January 2019-October 2021) of Patents Related to Next-Generation Sequencing
  • Figure 34: Share of Global Molecular Diagnostics Market (by Product), $Million, 2020 and 2031
  • Figure 35: Share of Global Molecular Diagnostics Market (by Product), Thousand Units, 2020 and 2031
  • Figure 36: Global Molecular Diagnostics Market (Systems), $Million, 2020-2031
  • Figure 37: Global Molecular Diagnostics Market (Systems), Thousand Units, 2020-2031
  • Figure 38: General Workflow of a Molecular Diagnostic Kit
  • Figure 39: Global Molecular Diagnostics Market (Kits and Consumables), $Million, 2020-2031
  • Figure 40: Global Molecular Diagnostics Market (Kits and Consumables), Thousand Units, 2020-2031
  • Figure 41: Aspects of Software Development
  • Figure 42: Global Molecular Diagnostics Market (Software and Other Products), $Million, 2020-2031
  • Figure 43: Global Molecular Diagnostics Market (Software and Other Products), Thousand Units, 2020-2031
  • Figure 44: Global Molecular Diagnostics Market (by Testing Location)
  • Figure 45: Share of Global Molecular Diagnostics Market (by Testing Location), $Million, 2020 and 2031
  • Figure 46: Global Molecular Diagnostics Market (Laboratory Testing), $Million, 2020-2031
  • Figure 47: Global Molecular Diagnostics Market (Point-of-Care Testing), $Million, 2020-2031
  • Figure 48: Share of Global Molecular Diagnostics Market (by Technology), $Million, 2020 and 2031
  • Figure 49: Global Molecular Diagnostics Market (Polymerase Chain Reaction), $Million, 2020-2031
  • Figure 50: Global Molecular Diagnostics Market (Polymerase Chain Reaction), Thousand Units, 2020-2031
  • Figure 51: Global Molecular Diagnostics Market (Next-Generation Sequencing), $Million, 2020-2031
  • Figure 52: Global Molecular Diagnostics Market (Next-Generation Sequencing), Thousand Units, 2020-2031
  • Figure 53: Global Molecular Diagnostics Market (Isothermal Nucleic Acid Amplification Technology), $Million, 2020-2031
  • Figure 54: Global Molecular Diagnostics Market (Isothermal Nucleic Acid Amplification Technology), Thousand Units, 2020-2031
  • Figure 55: Global Molecular Diagnostics Market (Microarray), $Million, 2020-2031
  • Figure 56: Global Molecular Diagnostics Market (Microarray), Thousand Units, 2020-2031
  • Figure 57: Global Molecular Diagnostics Market (ISH), $Million, 2020-2031
  • Figure 58: Global Molecular Diagnostics Market (ISH), Thousand Units, 2020-2031
  • Figure 59: Global Molecular Diagnostics Market (IHC), $Million, 2020-2031
  • Figure 60: Global Molecular Diagnostics Market (IHC), Thousand Units, 2020-2031
  • Figure 61: Global Molecular Diagnostics Market (Other Technologies), $Million, 2020-2031
  • Figure 62: Global Molecular Diagnostics Market (Other Technologies), Thousand Units, 2020-2031
  • Figure 63: Global Molecular Diagnostics Market (by Application), $Million, 2020 and 2031
  • Figure 64: Global Molecular Diagnostics Market (Core Molecular Diagnostics), $Million, 2020-2031
  • Figure 65: Global Molecular Diagnostics Market (Core Molecular Diagnostics), Thousand Units, 2020-2031
  • Figure 66: Global Molecular Diagnostics Market (by Core Molecular Diagnostics), $Million, 2020 and 2031
  • Figure 67: Global Molecular Diagnostics Market (Infectious Disease), $Million, 2020-2031
  • Figure 68: Global Molecular Diagnostics Market (Infectious Disease), Thousand Units, 2020-2031
  • Figure 69: Global Molecular Diagnostics Market (by Infectious Disease), $Million, 2020-2031
  • Figure 70: Global Molecular Diagnostics Market (by Infectious Disease), Thousand Units, 2020-2031
  • Figure 71: Global Molecular Diagnostics Market (Respiratory Infections), $Million, 2020-2031
  • Figure 72: Global Molecular Diagnostics Market (Respiratory Infections), Thousand Units, 2020-2031
  • Figure 73: Global Molecular Diagnostics Market (Influenza A and B), $Million, 2020-2031
  • Figure 74: Global Molecular Diagnostics Market (Influenza A and B), Thousand Units, 2020-2031
  • Figure 75: Global Molecular Diagnostics Market (COVID-19 Infections), $Million, 2020-2031
  • Figure 76: Global Molecular Diagnostics Market (COVID-19 Infections), Thousand Units, 2020-2031
  • Figure 77: Global Molecular Diagnostics Market (Respiratory Syncytial Virus), $Million, 2020-2031
  • Figure 78: Global Molecular Diagnostics Market (Respiratory Syncytial Virus), Thousand Units, 2020-2031
  • Figure 79: Global Molecular Diagnostics Market (Mycoplasma Infections), $Million, 2020-2031
  • Figure 80: Global Molecular Diagnostics Market (Mycoplasma Infections), Thousand Units, 2020-2031
  • Figure 81: Global Molecular Diagnostics Market (Pertussis), $Million, 2020-2031
  • Figure 82: Global Molecular Diagnostics Market (Pertussis), Thousand Units, 2020-2031
  • Figure 83: Global Molecular Diagnostics Market (Other Respiratory Infections), $Million, 2020-2031
  • Figure 84: Global Molecular Diagnostics Market (Other Respiratory Infections), Thousand Units, 2020-2031
  • Figure 85: Global Molecular Diagnostics Market (Hepatitis B), $Million, 2020-2031
  • Figure 86: Global Molecular Diagnostics Market (Hepatitis B), Thousand Units, 2020-2031
  • Figure 87: Global Molecular Diagnostics Market (HIV-AIDS), $Million, 2020-2031
  • Figure 88: Global Molecular Diagnostics Market (HIV-AIDS), Thousand Units, 2020-2031
  • Figure 89: Global Molecular Diagnostics Market (HPV), $Million, 2020-2031
  • Figure 90: Global Molecular Diagnostics Market (HPV), Thousand Units, 2020-2031
  • Figure 91: Global Molecular Diagnostics Market (Herpes Simplex Virus), $Million, 2020-2031
  • Figure 92: Global Molecular Diagnostics Market (Herpes Simplex Virus), Thousand Units, 2020-2031
  • Figure 93: Global Molecular Diagnostics Market (Neisseria Gonorrhoeae), $Million, 2020-2031
  • Figure 94: Global Molecular Diagnostics Market (Neisseria Gonorrhoeae), Thousand Units, 2020-2031
  • Figure 95: Global Molecular Diagnostics Market (Other STIs), $Million, 2020-2031
  • Figure 96: Global Molecular Diagnostics Market (Other STIs), Thousand Units, 2020-2031
  • Figure 97: Global Molecular Diagnostics Market (Hereditary Genetic Testing), $Million, 2020-2031
  • Figure 98: Global Molecular Diagnostics Market (Hereditary Genetic Testing), Thousand Units, 2020-2031
  • Figure 99: Global Molecular Diagnostics Market (Blood Donor Screening), $Million, 2020-2031
  • Figure 100: Global Molecular Diagnostics Market (Blood Donor Screening), Thousand Units, 2020-2031
  • Figure 101: Clinical Uses of Molecular Diagnostics in Cancer
  • Figure 102: Global Molecular Diagnostics Market (Oncology), $Million, 2020-2031
  • Figure 103: Global Molecular Diagnostics Market (Oncology), Thousand Units, 2020-2031
  • Figure 104: Global Molecular Diagnostics Market (Human Leukocyte Antigen Testing), $Million, 2020-2031
  • Figure 105: Global Molecular Diagnostics Market (Human Leukocyte Antigen Testing), Thousand Units, 2020-2031
  • Figure 106: Global Molecular Diagnostics Market (Other Molecular Diagnostics Applications), $Million, 2020-2031
  • Figure 107: Global Molecular Diagnostics Market (Other Molecular Diagnostics Applications), Thousand Units, 2020-2031
  • Figure 108: Global Molecular Diagnostics Market (Reproductive Genetics), $Million, 2020-2031
  • Figure 109: Global Molecular Diagnostics Market (Reproductive Genetics), Thousand Units, 2020-2031
  • Figure 110: Global Molecular Diagnostics Market (by Reproductive Genetics), $Million, 2020 and 2031
  • Figure 111: Global Molecular Diagnostics Market (Carrier Screening), $Million, 2020-2031
  • Figure 112: Global Molecular Diagnostics Market (Carrier Screening), Thousand Units, 2020-2031
  • Figure 113: Global Molecular Diagnostics Market (NIPT), $Million, 2020-2031
  • Figure 114: Global Molecular Diagnostics Market (NIPT), Thousand Units, 2020-2031
  • Figure 115: Global Molecular Diagnostics Market (Pre-Implantation Genetic Testing), $Million, 2020-2031
  • Figure 116: Global Molecular Diagnostics Market (Pre-Implantation Genetic Testing), Thousand Units, 2020-2031
  • Figure 117: Global Molecular Diagnostics Market (Infertility Genetic Testing), $Million, 2020-2031
  • Figure 118: Global Molecular Diagnostics Market (Infertility Genetic Testing), Thousand Units, 2020-2031
  • Figure 119: Global Molecular Diagnostics Market (Companion Diagnostics), $Million, 2020-2031
  • Figure 120: Global Molecular Diagnostics Market (Companion Diagnostics), Thousand Units, 2020-2031
  • Figure 121: Global Molecular Diagnostics Market (Liquid Biopsy), $Million, 2020-2031
  • Figure 122: Global Molecular Diagnostics Market (Liquid Biopsy), Thousand Units, 2020-2031
  • Figure 123: Global Molecular Diagnostics Market (Other Applications), $Million, 2020-2031
  • Figure 124: Global Molecular Diagnostics Market (Other Applications), Thousand Units, 2020-2031
  • Figure 125: Share of Global Molecular Diagnostics Market (by End User), $Million, 2020 and 2031
  • Figure 126: Share of Global Molecular Diagnostics Market (by End User), Thousand Units, 2020 and 2031
  • Figure 127: Global Molecular Diagnostics Market (Hospitals), $Million, 2020-2031
  • Figure 128: Global Molecular Diagnostics Market (Hospitals), Thousand Units, 2020-2031
  • Figure 129: Hospitals Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
  • Figure 130: Hospitals Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
  • Figure 131: Hospitals Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031
  • Figure 132: Hospitals Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031
  • Figure 133: Hospitals Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031
  • Figure 134: Hospitals Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031
  • Figure 135: Hospitals Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031
  • Figure 136: Hospitals Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031
  • Figure 137: Hospitals Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031
  • Figure 138: Hospitals Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031
  • Figure 139: Hospitals Molecular Diagnostics Market, Pertussis, $Million, 2020-2031
  • Figure 140: Hospitals Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031
  • Figure 141: Hospitals Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031
  • Figure 142: Hospitals Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
  • Figure 143: Hospitals Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
  • Figure 144: Hospitals Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
  • Figure 145: Diagnostic Centers Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031
  • Figure 146: Hospitals Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031
  • Figure 147: Diagnostic Centers Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031
  • Figure 148: Hospitals Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031
  • Figure 149: Diagnostic Centers Molecular Diagnostics Market, HPV, $Million, 2020-2031
  • Figure 150: Hospitals Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031
  • Figure 151: Diagnostic Centers Molecular Diagnostics Market, HSV, $Million, 2020-2031
  • Figure 152: Hospitals Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031
  • Figure 153: Hospitals Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031
  • Figure 154: Hospitals Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031
  • Figure 155: Hospitals Molecular Diagnostics Market, Other STIs, $Million, 2020-2031
  • Figure 156: Hospitals Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031
  • Figure 157: Global Molecular Diagnostics Market (Diagnostic Centers), $Million, 2020-2031
  • Figure 158: Global Molecular Diagnostics Market (Diagnostic Centers), Thousand Units, 2020-2031
  • Figure 159: Diagnostic Centers Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
  • Figure 160: Diagnostic Centers Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
  • Figure 161: Diagnostic Centers Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031
  • Figure 162: Diagnostic Centers Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031
  • Figure 163: Diagnostic Centers Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031
  • Figure 164: Diagnostic Centers Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031
  • Figure 165: Diagnostic Centers Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031
  • Figure 166: Diagnostic Centers Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031
  • Figure 167: Diagnostic Centers Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031
  • Figure 168: Diagnostic Centers Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031
  • Figure 169: Diagnostic Centers Molecular Diagnostics Market, Pertussis, $Million, 2020-2031
  • Figure 170: Diagnostic Centers Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031
  • Figure 171: Diagnostic Centers Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031
  • Figure 172: Diagnostic Centers Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
  • Figure 173: Diagnostic Centers Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
  • Figure 174: Diagnostic Centers Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
  • Figure 175: Diagnostic Centers Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031
  • Figure 176: Diagnostic Centers Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031
  • Figure 177: Diagnostic Centers Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031
  • Figure 178: Diagnostic Centers Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031
  • Figure 179: Diagnostic Centers Molecular Diagnostics Market, HPV, $Million, 2020-2031
  • Figure 180: Diagnostic Centers Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031
  • Figure 181: Diagnostic Centers Molecular Diagnostics Market, HSV, $Million, 2020-2031
  • Figure 182: Diagnostic Centers Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031
  • Figure 183: Diagnostic Centers Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031
  • Figure 184: Diagnostic Centers Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031
  • Figure 185: Diagnostic Centers Molecular Diagnostics Market, Other STIs, $Million, 2020-2031
  • Figure 186: Diagnostic Centers Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031
  • Figure 187: Global Molecular Diagnostics Market (Out-Patient Clinics/General Practitioners), $Million, 2020-2031
  • Figure 188: Global Molecular Diagnostics Market (Out-Patient Clinics/General Practitioners), Thousand Units, 2020-2031
  • Figure 189: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
  • Figure 190: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
  • Figure 191: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031
  • Figure 192: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031
  • Figure 193: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031
  • Figure 194: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031
  • Figure 195: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031
  • Figure 196: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031
  • Figure 197: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031
  • Figure 198: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031
  • Figure 199: Diagnostic Centers Molecular Diagnostics Market, Pertussis, $Million, 2020-2031
  • Figure 200: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031
  • Figure 201: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031
  • Figure 202: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
  • Figure 203: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
  • Figure 204: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
  • Figure 205: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031
  • Figure 206: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031
  • Figure 207: Diagnostic Centers Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031
  • Figure 208: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031
  • Figure 209: Diagnostic Centers Molecular Diagnostics Market, HPV, $Million, 2020-2031
  • Figure 210: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031
  • Figure 211: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, HSV, $Million, 2020-2031
  • Figure 212: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031
  • Figure 213: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031
  • Figure 214: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031
  • Figure 215: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Other STIs, $Million, 2020-2031
  • Figure 216: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031
  • Figure 217: Global Molecular Diagnostics Market (Research Laboratories), $Million, 2020-2031
  • Figure 218: Global Molecular Diagnostics Market (Research Laboratories), Thousand Units, 2020-2031
  • Figure 219: Research Laboratories Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
  • Figure 220: Research Laboratories Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
  • Figure 221: Research Laboratories Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031
  • Figure 222: Research Laboratories Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031
  • Figure 223: Research Laboratories Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031
  • Figure 224: Research Laboratories Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031
  • Figure 225: Research Laboratories Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031
  • Figure 226: Research Laboratories Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031
  • Figure 227: Research Laboratories Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031
  • Figure 228: Research Laboratories Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031
  • Figure 229: Research Laboratories Molecular Diagnostics Market, Pertussis, $Million, 2020-2031
  • Figure 230: Research Laboratories Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
  • Figure 231: Research Laboratories Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031
  • Figure 232: Research Laboratories Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
  • Figure 233: Research Laboratories Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
  • Figure 234: Research Laboratories Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
  • Figure 235: Research Laboratories Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031
  • Figure 236: Research Laboratories Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031
  • Figure 237: Research Laboratories Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031
  • Figure 238: Research Laboratories Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031
  • Figure 239: Research Laboratories Molecular Diagnostics Market, HPV, $Million, 2020-2031
  • Figure 240: Research Laboratories Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031
  • Figure 241: Research Laboratories Molecular Diagnostics Market, HSV, $Million, 2020-2031
  • Figure 242: Research Laboratories Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031
  • Figure 243: Research Laboratories Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031
  • Figure 244: Research Laboratories Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031
  • Figure 245: Research Laboratories Molecular Diagnostics Market, Other STIs, $Million, 2020-2031
  • Figure 246: Research Laboratories Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031
  • Figure 247: Global Molecular Diagnostics Market (Other End Users), $Million, 2020-2031
  • Figure 248: Global Molecular Diagnostics Market (Other End Users), Thousand Units, 2020-2031
  • Figure 249: Global Molecular Diagnostics Market (by Region), $Million, 2020-2031
  • Figure 250: Share of North America Molecular Diagnostics Market Revenue (by Country), $Million, 2020 and 2031
  • Figure 251: North America Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 252: North America Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 253: North America: Market Dynamics
  • Figure 254: North America Molecular Diagnostics Market (by Application), $Million, 2020 and 2031
  • Figure 255: North America Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
  • Figure 256: North America Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
  • Figure 257: North America Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031
  • Figure 258: North America Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031
  • Figure 259: North America Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031
  • Figure 260: North America Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031
  • Figure 261: North America Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031
  • Figure 262: North America Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031
  • Figure 263: North America Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031
  • Figure 264: North America Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031
  • Figure 265: North America Molecular Diagnostics Market, Pertussis, $Million, 2020-2031
  • Figure 266: North America Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031
  • Figure 267: North America Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031
  • Figure 268: North America Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
  • Figure 269: North America Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
  • Figure 270: North America Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
  • Figure 271: North America Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031
  • Figure 272: North America Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031
  • Figure 273: North America Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031
  • Figure 274: North America Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031
  • Figure 275: North America Molecular Diagnostics Market, HPV, $Million, 2020-2031
  • Figure 276: North America Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031
  • Figure 277: North America Molecular Diagnostics Market, HSV, $Million, 2020-2031
  • Figure 278: North America Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031
  • Figure 279: North America Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031
  • Figure 280: North America Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031
  • Figure 281: North America Molecular Diagnostics Market, Other STIs, $Million, 2020-2031
  • Figure 282: North America Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031
  • Figure 283: North America Molecular Diagnostics Market (by End User), $Million, 2020 and 2031
  • Figure 284: U.S. Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 285: U.S. Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 286: Canada Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 287: Canada Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 288: Europe Molecular Diagnostics Market (by Country), $Million, 2020 and 2031
  • Figure 289: Europe Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 290: Europe Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 291: Europe: Market Dynamics
  • Figure 292: Europe Molecular Diagnostics Market (by Application), $Million
  • Figure 293: Europe Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
  • Figure 294: Europe Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
  • Figure 295: Europe Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031
  • Figure 296: Europe Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031
  • Figure 297: Europe Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031
  • Figure 298: Europe Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031
  • Figure 299: Europe Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031
  • Figure 300: Europe Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031
  • Figure 301: Europe Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031
  • Figure 302: Europe Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031
  • Figure 303: Europe Molecular Diagnostics Market, Pertussis, $Million, 2020-2031
  • Figure 304: Europe Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031
  • Figure 305: Europe Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031
  • Figure 306: Europe Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
  • Figure 307: Europe Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
  • Figure 308: Europe Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
  • Figure 309: Europe Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031
  • Figure 310: Europe Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031
  • Figure 311: Europe Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031
  • Figure 312: Europe Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031
  • Figure 313: Europe Molecular Diagnostics Market, HPV, $Million, 2020-2031
  • Figure 314: Europe Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031
  • Figure 315: Europe Molecular Diagnostics Market, HSV, $Million, 2020-2031
  • Figure 316: Europe Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031
  • Figure 317: Europe Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031
  • Figure 318: Europe Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031
  • Figure 319: Europe Molecular Diagnostics Market, Other STIs, $Million, 2020-2031
  • Figure 320: Europe Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031
  • Figure 321: Europe Molecular Diagnostics Market (by End User), $Million, 2020 and 2031
  • Figure 322: Germany Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 323: Germany Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 324: U.K. Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 325: U.K. Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 326: France Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 327: France Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 328: Italy Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 329: Italy Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 330: Spain Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 331: Spain Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 332: Rest-of-Europe Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 333: Rest-of-Europe Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 334: Asia-Pacific Molecular Diagnostics Market (by Country), $Million, 2020 and 2031
  • Figure 335: Asia-Pacific Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 336: Asia-Pacific Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 337: Asia-Pacific: Market Dynamics
  • Figure 338: Asia-Pacific Molecular Diagnostics Market (by Application), $Million, 2020 and 2031
  • Figure 339: Asia-Pacific Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
  • Figure 340: Asia-Pacific Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
  • Figure 341: Asia-Pacific Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031
  • Figure 342: Asia-Pacific Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031
  • Figure 343: Asia-Pacific Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031
  • Figure 344: Asia-Pacific Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031
  • Figure 345: Asia-Pacific Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031
  • Figure 346: Asia-Pacific Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031
  • Figure 347: Asia-Pacific Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031
  • Figure 348: Asia-Pacific Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031
  • Figure 349: Asia-Pacific Molecular Diagnostics Market, Pertussis, $Million, 2020-2031
  • Figure 350: Asia-Pacific Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031
  • Figure 351: Asia-Pacific Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031
  • Figure 352: Asia-Pacific Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
  • Figure 353: Asia-Pacific Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
  • Figure 354: Asia-Pacific Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
  • Figure 355: Asia-Pacific Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031
  • Figure 356: Asia-Pacific Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031
  • Figure 357: Asia-Pacific Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031
  • Figure 358: Asia-Pacific Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031
  • Figure 359: Asia-Pacific Molecular Diagnostics Market, HPV, $Million, 2020-2031
  • Figure 360: Asia-Pacific Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031
  • Figure 361: Asia-Pacific Molecular Diagnostics Market, HSV, $Million, 2020-2031
  • Figure 362: Asia-Pacific Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031
  • Figure 363: Asia-Pacific Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031
  • Figure 364: Asia-Pacific Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031
  • Figure 365: Asia-Pacific Molecular Diagnostics Market, Other STIs, $Million, 2020-2031
  • Figure 366: Asia-Pacific Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031
  • Figure 367: Asia-Pacific Molecular Diagnostics Market (by End User), $Million, 2020 and 2031
  • Figure 368: China Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 369: China Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 370: India Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 371: India Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 372: Japan Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 373: Japan Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 374: Australia Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 375: Australia Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 376: Singapore Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 377: Singapore Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 378: Rest-of-Asia-Pacific Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 379: Rest-of-Asia-Pacific Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 380: Latin America Molecular Diagnostics Market (by Country), $Million 2020-2031
  • Figure 381: Latin America Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 382: Latin America Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 383: LATAM: Market Dynamics
  • Figure 384: Latin America Molecular Diagnostics Market (by Application), $Million, 2020 and 2031
  • Figure 385: Latin America Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
  • Figure 386: Latin America Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
  • Figure 387: Latin America Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031
  • Figure 388: Latin America Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031
  • Figure 389: Latin America Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031
  • Figure 390: Latin America Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031
  • Figure 391: Latin America Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031
  • Figure 392: Latin America Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031
  • Figure 393: Latin America Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031
  • Figure 394: Latin America Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031
  • Figure 395: Latin America Molecular Diagnostics Market, Pertussis, $Million, 2020-2031
  • Figure 396: Latin America Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031
  • Figure 397: Latin America Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031
  • Figure 398: Latin America Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
  • Figure 399: Latin America Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
  • Figure 400: Latin America Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
  • Figure 401: Latin America Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031
  • Figure 402: Latin America Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031
  • Figure 403: Latin America Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031
  • Figure 404: Latin America Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031
  • Figure 405: Latin America Molecular Diagnostics Market, HPV, $Million, 2020-2031
  • Figure 406: Latin America Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031
  • Figure 407: Latin America Molecular Diagnostics Market, HSV, $Million, 2020-2031
  • Figure 408: Latin America Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031
  • Figure 409: Latin America Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031
  • Figure 410: Latin America Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031
  • Figure 411: Latin America Molecular Diagnostics Market, Other STIs, $Million, 2020-2031
  • Figure 412: Latin America Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031
  • Figure 413: Latin America Molecular Diagnostics Market (by End User), $Million, 2020 and 2031
  • Figure 414: Brazil Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 415: Brazil Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 416: Mexico Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 417: Mexico Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 418: Rest-of-Latin America Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 419: Rest-of-Asia-Pacific Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 420: Rest-of-the-World Molecular Diagnostics Market, $Million, 2020-2031
  • Figure 421: Rest-of-the-World Molecular Diagnostics Market, Thousand Units, 2020-2031
  • Figure 422: Rest-of-the-World Molecular Diagnostics Market (by Application), $Million, 2020 and 2031
  • Figure 423: Rest-of-the-World Molecular Diagnostics Market (by End User), $Million, 2020 and 2031
  • Figure 424: Rest-of-the-World Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
  • Figure 425: Rest-of-the-World Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
  • Figure 426: Share of Rest-of-the-World Market (by Respiratory Infections), $Million, 2020 and 2031
  • Figure 427: Rest-of-the-World Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
  • Figure 428: Rest-of-the-World Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
  • Figure 429: Share of Rest-of-the-World Market (by Sexually Transmitted Infections), $Million, 2020 and 2031
  • Figure 430: Share of Key Companies Profiled
  • Figure 431: Abbott: Overall Product Portfolio
  • Figure 432: Abbott: Overall Financials, 2018-2020
  • Figure 433: Abbott: Revenue (by Segment), 2018-2020
  • Figure 434: Abbott: Revenue (by Region), 2018-2020
  • Figure 435: Abbott: R&D Expenditure, 2018-2020
  • Figure 436: Abbott: SWOT Analysis
  • Figure 437: Agilent Technologies, Inc.: Overall Product Portfolio
  • Figure 438: Agilent Technologies, Inc.: Overall Financials, 2018-2020
  • Figure 439: Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020
  • Figure 440: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
  • Figure 441: Agilent Technologies, Inc.: R&D Expenditure, 2018-2020
  • Figure 442: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 443: Becton, Dickinson and Company (BD): Overall Product Portfolio
  • Figure 444: Becton, Dickinson and Company (BD): Overall Financials, 2018-2020
  • Figure 445: Becton, Dickinson and Company (BD): Revenue (by Segment), 2018-2020
  • Figure 446: Becton, Dickinson and Company (BD): Revenue (by Region), 2018-2020
  • Figure 447: Becton, Dickinson and Company (BD): R&D Expenditure, 2018-2020
  • Figure 448: Becton, Dickinson and Company: SWOT Analysis
  • Figure 449: bioMérieux SA: Overall Product Portfolio
  • Figure 450: bioMérieux SA: Overall Financials, 2018-2020
  • Figure 451: bioMérieux SA: Revenue (by Segment), 2018-2020
  • Figure 452: bioMérieux SA: Revenue (by Region), 2018-2020
  • Figure 453: bioMérieux SA: R&D Expenditure, 2018-2020
  • Figure 454: bioMérieux SA: SWOT Analysis
  • Figure 455: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
  • Figure 456: Bio-Rad Laboratories, Inc.: Overall Financials, 2018-2020
  • Figure 457: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2018-2020
  • Figure 458: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2018-2020
  • Figure 459: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2018-2020
  • Figure 460: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 461: Danaher: Overall Product Portfolio
  • Figure 462: Danaher: Overall Financials, 2018-2020
  • Figure 463: Danaher: Revenue (by Segment), 2018-2020
  • Figure 464: Danaher: Revenue (by Region), 2018-2020
  • Figure 465: Danaher: R&D Expenditure, 2018-2020
  • Figure 466: Danaher: SWOT Analysis
  • Figure 467: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
  • Figure 468: F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020
  • Figure 469: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2018-2020
  • Figure 470: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2018-2020
  • Figure 471: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020
  • Figure 472: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 473: Guardant Health: Overall Product Portfolio
  • Figure 474: Guardant Health: Overall Financials, 2018-2020
  • Figure 475: Guardant Health: Revenue (by Segment), 2018-2020
  • Figure 476: Guardant Health: R&D Expenditure, 2018-2020
  • Figure 477: Guardant Health: SWOT Analysis
  • Figure 478: HTG Molecular Diagnostics, Inc.: Overall Product Portfolio
  • Figure 479: HTG Molecular Diagnostics, Inc.: Overall Financials, 2018-2020
  • Figure 480: HTG Molecular Diagnostics, Inc.: Revenue (by Segment), 2018-2020
  • Figure 481: HTG Molecular Diagnostics, Inc.: R&D Expenditure, 2018-2020
  • Figure 482: HTG Molecular Diagnostics, Inc.: SWOT Analysis
  • Figure 483: Illumina, Inc.: Overall Product Portfolio
  • Figure 484: Illumina, Inc.: Overall Financials, 2018-2020
  • Figure 485: Illumina, Inc.: Revenue (by Segment), 2018-2020
  • Figure 486: Illumina, Inc.: Revenue (by Region), 2018-2020
  • Figure 487: Illumina, Inc.: R&D Expenditure, 2018-2020
  • Figure 488: Illumina, Inc.: SWOT Analysis
  • Figure 489: Invivoscribe, Inc.: Overall Product Portfolio
  • Figure 490: Invivoscribe, Inc.: SWOT Analysis
  • Figure 491: ICON plc: Overall Product Portfolio
  • Figure 492: ICON plc: SWOT Analysis
  • Figure 493: LungLife AI, Inc.: Overall Product Portfolio
  • Figure 494: LungLife AI, Inc.: SWOT Analysis
  • Figure 495: QIAGEN: Overall Product Portfolio
  • Figure 496: QIAGEN: Overall Financials, 2018-2020
  • Figure 497: QIAGEN: Revenue (by Segment), 2018-2020
  • Figure 498: QIAGEN: Revenue (by Region), 2018-2020
  • Figure 499: QIAGEN: R&D Expenditure, 2018-2020
  • Figure 500: QIAGEN: SWOT Analysis
  • Figure 501: QuantuMDx Group Ltd.: Overall Product Portfolio
  • Figure 502: QuantuMDx Group Ltd.: SWOT Analysis
  • Figure 503: Siemens Healthcare GmbH: Overall Product Portfolio
  • Figure 504: Siemens Healthcare GmbH: Overall Financials, 2018-2020
  • Figure 505: Siemens Healthcare GmbH: Revenue (by Segment), 2018-2020
  • Figure 506: Siemens Healthcare GmbH: Revenue (by Region), 2018-2020
  • Figure 507: Siemens Healthcare GmbH: R&D Expenditure, 2018-2020
  • Figure 508: Siemens Healthcare GmbH: SWOT Analysis
  • Figure 509: Thermo Fisher Scientific Inc.: Overall Product Portfolio
  • Figure 510: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020
  • Figure 511: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2018-2020
  • Figure 512: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
  • Figure 513: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
  • Figure 514: Thermo Fisher Scientific Inc.: SWOT Analysis

List of Tables

  • Table 1: Biomarkers for Various Diseases
  • Table 2: FDA-Approved Drugs with a Companion Diagnostic
  • Table 3: COVID-19 Impact on Global Molecular Diagnostics Market
  • Table 4: Products Launched by Various Manufacturers for Molecular Diagnostics Research
  • Table 5: Registration Criteria for IVD Medical Devices as per the CFDA
  • Table 6: Approved Next-Generation Sequencing (NGS) Panels in Japan
  • Table 7: Pathogens Responsible for Different Respiratory Infections
  • Table 8: Key Biomarker Testing Products for Respiratory Infections Offered by Major Market Players
  • Table 9: Genetic Tests for Certain Applications
  • Table 10: Examples of Molecular Diagnostics in Cancer
  • Table 11: North America Molecular Diagnostics Market (by End User), Thousand Units, 2020, 2025, and 2031
  • Table 12: Europe Molecular Diagnostics Market (by Application), Thousand Units, 2020, 2025, and 2031
  • Table 13: Europe Molecular Diagnostics Market (by End User), Thousand Units, 2020,2025 and 2031
  • Table 14: Asia-Pacific Molecular Diagnostics Market (by Application), Thousand Units, 2020, 2025, and 2031
  • Table 15: Asia-Pacific Molecular Diagnostics Market (by End User), Thousand Units, 2020, 2025, and 2031
  • Table 16: Latin America Molecular Diagnostics Market (by Application), Thousand Units, 2020, 2025, and 2031
  • Table 17: Latin America Molecular Diagnostics Market (by End User), Thousand Units, 2020, 2025, and 2031
  • Table 18: Rest-of-the-World Molecular Diagnostics Market (by Application), Thousand Units, 2020, 2025, and 2031
  • Table 19: Rest-of-the-World Molecular Diagnostics Market (by End User), Thousand Units, 2020, 2025, and 2031
目次
Product Code: BHP0678SB

“Global Molecular Diagnostics Market to Reach $24,228.0 Million by 2031.”

Market Report Coverage - Molecular Diagnostics

Market Segmentation

  • Products (Kits and Consumables, Systems, Software and Other Products)
  • Testing Location (Laboratory Testing and Point-of-Care (POC) Testing)
  • Application (Core Molecular Diagnostics, Reproductive Genetics, Companion Diagnostics (CDx), Liquid Biopsy, and Others)
  • Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing, Isothermal Nucleic Acid Amplification Technology (INAAT), Microarray, In-situ Hybridization (ISH), Immunohistochemistry (IHC) and Other Technologies)
  • End User (Hospitals, Diagnostics Centers, Out-Patient Clinics/General Practitioners, Research Laboratories, and Other End Users)

Regional Segmentation

  • North America: U.S., Canada
  • Europe: Germany, France, Italy, U.K., Spain, and Rest-of- Europe
  • Asia-Pacific: Japan, China, India, Australia, Singapore, and Rest-of-Asia-Pacific
  • Latin America: Brazil, Mexico, Rest-of-Latin America
  • Rest-of-the-World (RoW)

Market Growth Drivers

  • A Highly Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
  • Growth in the Biomarker Identification Market and Advancements in Molecular Techniques
  • Increase in Awareness and Acceptance of Personalized Medicines on a Global Level
  • Significant External Funding for Executing Research and Development Exercises

Market Challenges

  • Uncertain Reimbursement Scenario
  • Lack of High-Complexity Testing Centers
  • Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests

Market Opportunities

  • Massive Scope for Adoption of Molecular Diagnostics in Emerging Nations
  • Rise of Next-Generation Ultrasensitive Molecular Diagnostics
  • Novel Revenue Streams

Key Companies Profiled

Abbott, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), bioMerieux SA, Bio-Rad Laboratories, Inc., Danaher, F. Hoffmann-La Roche Ltd, Guardant Health, HTG Molecular Diagnostics, Inc., Illumina, Inc., Invivoscribe, Inc., ICON plc, LungLife AI, Inc., QIAGEN, QuantuMDx Group Ltd., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

  • How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment?
  • What are the major market drivers, challenges, and opportunities in the global molecular diagnostics market?
  • What are the underlying structures resulting in the emerging trends within the global molecular diagnostics market?
  • How is each segment of the global molecular diagnostics market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
  • What are the key developmental strategies implemented by the major players to sustain in the competitive market?
  • What are the key regulatory implications in developed and developing regions for molecular diagnostics?
  • Who are the leading players with significant offerings to the global molecular diagnostics market? What is the current market dominance for each of these leading players?
  • What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which molecular diagnostic product type has the most promising growth?
  • What are the key applications in the global molecular diagnostics market? What are the major segments of these applications? What technologies are dominating these application segments?
  • What are the major technologies that are employed in the global molecular diagnostics market? Which is the dominating technology?
  • Who are the primary end-users of the global molecular diagnostics market? Which is the fastest-growing end-user segment in the global molecular diagnostics market?
  • Who are the key manufacturers in the global molecular diagnostics market, and what are their contributions? Also, what is the growth potential of each major molecular diagnostics manufacturer?
  • What is the scope of the global molecular diagnostics market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which molecular diagnostics application and end user dominate these regions?
  • What are the emerging trends in the global molecular diagnostics market? How are these trends revolutionizing the diagnostic procedure?
  • Which technologies are anticipated to break through the current molecular diagnostic regime?
  • Which companies are anticipated to be highly disruptive in the future and why?
  • What are the regulatory procedures that are required to unify the approval process for emerging molecular diagnostics? How will these enhance the reimbursement scenario?
  • What are the gaps in regularizing optimum molecular diagnostic adoption in regular healthcare routines? How are these gaps being tackled?

Market Overview

Diagnostic tests provide critical insights at every stage of medical care - right from the genetic tests providing information about personalized cancer treatment to the microbial culture identifying accurate antibiotics against an infection. The importance of diagnostic tests throughout the entire procedure (i.e., prevention, detection, diagnosis, treatment, and successful management of health conditions) of treating an individual for a particular disease is as consequential as the treatment itself. It has been subjected to extensive research for further refinement of the same.

Our healthcare experts have found the molecular diagnostics market to be one of the stable markets, and the global market is predicted to grow from $10,914.6 million in 2020 to $24,228.0 million in 2031 and is expected to grow with a CAGR of 7.38% during the forecast period 2021-2031.

Factors fueling the growth of the market include a highly increasing prevalence of infectious diseases and various types of cancer, an increase in awareness and acceptance of personalized medicines on a global level, and significant external funding for executing research and development exercises. Despite rapid advanced industry growth, several key issues need to be addressed to facilitate future growth. Uncertain reimbursement scenarios, lack of high-complexity testing centers, and complex regulatory frameworks delaying the approval of new molecular diagnostic tests are hampering the market growth. Further, some of the opportunities, such as massive scope for the adoption of molecular diagnostics in emerging nations and the rise of next-generation ultrasensitive molecular diagnostics and novel revenue streams, provide growth to the market.

Within the research report, the market has been segmented based on product, testing location, application, technology, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the prevalence of infectious diseases and various types of cancer globally has created a buzz among companies to invest in advanced technologies such as molecular diagnostics.

Based on region, North America holds the largest share, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. However, the Asia-Pacific and Europe regions are anticipated to grow at the fastest CAGR during the forecast period.

Table of Contents

1. Markets

  • 1.1. Product Definition
    • 1.1.1. Definitions
    • 1.1.2. Inclusion and Exclusion
  • 1.2. Market Overview
  • 1.3. Historical Perspective
  • 1.4. Significant Technologies
  • 1.5. Classification of Molecular Diagnostics
  • 1.6. Global Footprint
  • 1.7. Global Molecular Diagnostics Market Size and Forecast - Realistic, Optimistic, and Conservative Growth Scenario
    • 1.7.1. Realistic Growth Scenario
    • 1.7.2. Conservative Growth Scenario
  • 1.8. Future Potential
    • 1.8.1. Optimistic Growth Scenario
  • 1.9. Market Dynamics
    • 1.9.1. Impact Analysis
    • 1.9.2. Market Drivers
      • 1.9.2.1. A Highly Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
      • 1.9.2.2. Growth in the Biomarker Identification Market and Advancements in Molecular Techniques
      • 1.9.2.3. Increase in Awareness and Acceptance of Personalized Medicines on a Global Level
      • 1.9.2.4. Significant External Funding for Executing Research and Development Exercises
    • 1.9.3. Market Restraints
      • 1.9.3.1. Uncertain Reimbursement Scenario
      • 1.9.3.2. Lack of High-Complexity Testing Centers
      • 1.9.3.3. Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests
    • 1.9.4. Market Opportunities
      • 1.9.4.1. Massive Scope for Adoption of Molecular Diagnostics in Emerging Nations
      • 1.9.4.2. Rise of Next-Generation Ultrasensitive Molecular Diagnostics
      • 1.9.4.3. Novel Revenue Streams
  • 1.1. COVID-19 Impact on Global Molecular Diagnostics Market
    • 1.10.1. Impact on Market Size
    • 1.10.2. Impact on Molecular Diagnostic Practices
  • 1.11. Competitive Landscape
    • 1.11.1. Acquisitions
    • 1.11.2. Synergistic Activities
    • 1.11.3. Product Launches and Upgradations
    • 1.11.4. Business Expansion
    • 1.11.5. Market Share Analysis, by Company
    • 1.11.6. Growth Share Analysis, by Technology
  • 1.12. Industry Insights
    • 1.12.1. Legal Requirements and Framework in the U.S.
    • 1.12.2. FDA Regulations
    • 1.12.3. Legal Requirements and Framework in Europe
      • 1.12.3.1. U.K.
      • 1.12.3.2. Germany
    • 1.12.4. Legal Requirements and Framework in Asia-Pacific
      • 1.12.4.1. China
      • 1.12.4.2. Japan
        • 1.12.4.2.1. Pharmaceuticals and Medical Devices Agency (PMDA)
        • 1.12.4.2.2. Ministry of Health, Labour, and Welfare (MHLW)
      • 1.12.4.3. India
  • 1.13. Patent Analysis
    • 1.13.1. Patent Filing Trend

2. Products

  • 2.1. Overview
    • 2.1.1. Systems
    • 2.1.2. Kits and Consumables
    • 2.1.3. Software and Other Products

3. Testing Location

  • 3.1. Overview
    • 3.1.1. Laboratory Testing
    • 3.1.2. Point-of-Care Testing

4. Technology

  • 4.1. Overview
    • 4.1.1. Polymerase Chain Reaction (PCR)
    • 4.1.2. Next-Generation Sequencing
    • 4.1.3. Isothermal Nucleic Acid Amplification Technology (INAAT)
    • 4.1.4. Microarray
    • 4.1.5. In-Situ Hybridization (ISH)
    • 4.1.6. Immunohistochemistry (IHC)
    • 4.1.7. Other Technologies

5. Application

  • 5.1. Overview
    • 5.1.1. Core Molecular Diagnostics
      • 5.1.1.1. Infectious Disease
        • 5.1.1.1.1. Respiratory Infections
          • 5.1.1.1.1.1. Influenza A and B
          • 5.1.1.1.1.2. COVID-19 Infections
          • 5.1.1.1.1.3. Respiratory Syncytial Virus
          • 5.1.1.1.1.4. Mycoplasma Infections
          • 5.1.1.1.1.5. Pertussis
          • 5.1.1.1.1.6. Other Respiratory Infections
        • 5.1.1.1.2. Sexual Transmitted Infections(STI)
          • 5.1.1.1.2.1. Common Pathogens Associated with Sexually Transmitted Infection
          • 5.1.1.1.2.2. Hepatitis B
          • 5.1.1.1.2.3. HIV-AIDS
          • 5.1.1.1.2.4. HPV
          • 5.1.1.1.2.5. Herpes Simplex Virus
          • 5.1.1.1.2.6. Neisseria Gonorrhoeae
          • 5.1.1.1.2.7. Other STIs
      • 5.1.1.2. Hereditary Genetic Testing
      • 5.1.1.3. Blood Donor Screening
      • 5.1.1.4. Oncology
      • 5.1.1.5. Human Leukocyte Antigen (HLA) Testing
      • 5.1.1.6. Other Molecular Diagnostics Applications
    • 5.1.2. Reproductive Genetics
      • 5.1.2.1. Carrier Screening
      • 5.1.2.2. Non-Invasive Pre-Natal Testing (NIPT)
      • 5.1.2.3. Pre-Implantation Genetic Testing
      • 5.1.2.4. Infertility Genetic Testing
    • 5.1.3. Companion Diagnostics (CDx)
    • 5.1.4. Liquid Biopsy
    • 5.1.5. Other Applications

6. End-User

  • 6.1. Overview
    • 6.1.1. Hospitals
      • 6.1.1.1. Hospitals, by Respiratory Infections Molecular Diagnostics Market
        • 6.1.1.1.1. Hospitals, by Influenza A and B
        • 6.1.1.1.2. Hospitals, by COVID-19 Infections
        • 6.1.1.1.3. Hospitals, by Respiratory Syncytial Virus
        • 6.1.1.1.4. Hospitals, by Mycoplasma Infection
        • 6.1.1.1.5. Hospitals, by Pertussis
        • 6.1.1.1.6. Hospitals, by Other Respiratory Infections
      • 6.1.1.2. Hospitals Sexually Transmitted Infections (STIs) Market
        • 6.1.1.2.1. Hospitals, by Hepatitis B
        • 6.1.1.2.2. Hospitals, by HIV AIDS
        • 6.1.1.2.3. Hospitals, by HPV
        • 6.1.1.2.4. Hospitals, by Herpes Simplex Virus(HSV)
        • 6.1.1.2.5. Hospitals, by Neisseria gonorrhoeae
        • 6.1.1.2.6. Hospitals, by Other STIs
    • 6.1.2. Diagnostic Centers
      • 6.1.2.1. Diagnostic Centers, by Respiratory Infections Molecular Diagnostics Market
        • 6.1.2.1.1. Diagnostic Centers, by Influenza A and B
        • 6.1.2.1.2. Diagnostic Centers, by COVID-19 Infections
        • 6.1.2.1.3. Diagnostic Centers, by Respiratory Syncytial Virus
        • 6.1.2.1.4. Diagnostic Centers, by Mycoplasma Infection
        • 6.1.2.1.5. Diagnostic Centers, by Pertussis
        • 6.1.2.1.6. Diagnostic Centers, by Other Respiratory Infections
      • 6.1.2.2. Diagnostic Centers Sexually Transmitted Infections (STIs) Market
        • 6.1.2.2.1. Diagnostic Centers, by Hepatitis B
        • 6.1.2.2.2. Diagnostic Centers, by HIV AIDS
        • 6.1.2.2.3. Diagnostic Centers, by HPV
        • 6.1.2.2.4. Diagnostic Centers, by Herpes Simplex Virus(HSV)
        • 6.1.2.2.5. Diagnostic Centers, by Neisseria gonorrhoeae
        • 6.1.2.2.6. Diagnostic Centers, by Other STIs
    • 6.1.3. Out-Patient Clinics/General Practitioners
      • 6.1.3.1. Out-Patient Clinics/General Practitioners, by Respiratory Infections Molecular Diagnostics Market
        • 6.1.3.1.1. Out-Patient Clinics/General Practitioners, by Influenza A and B
        • 6.1.3.1.2. Out-Patient Clinics/General Practitioners, by COVID-19 Infections
        • 6.1.3.1.3. Out-Patient Clinics/General Practitioners, by Respiratory Syncytial Virus
        • 6.1.3.1.4. Out-Patient Clinics/General Practitioners, by Mycoplasma Infection
        • 6.1.3.1.5. Out-Patient Clinics/General Practitioners, by Pertussis
        • 6.1.3.1.6. Out-Patient Clinics/General Practitioners, by Other Respiratory Infections
      • 6.1.3.2. Out-Patient Clinics/General Practitioners Sexually Transmitted Infections (STIs) Market
        • 6.1.3.2.1. Out-Patient Clinics/General Practitioners, by Hepatitis B
        • 6.1.3.2.2. Out-Patient Clinics/General Practitioners, by HIV AIDS
        • 6.1.3.2.3. Out-Patient Clinics/General Practitioners, by HPV
        • 6.1.3.2.4. Out-Patient Clinics/General Practitioners, by Herpes Simplex Virus(HSV)
        • 6.1.3.2.5. Out-Patient Clinics/General Practitioners, by Neisseria gonorrhoeae
        • 6.1.3.2.6. Out-Patient Clinics/General Practitioners, by Other STIs
    • 6.1.4. Research Laboratories
      • 6.1.4.1. Research Laboratories, by Respiratory Infections Molecular Diagnostics Market
        • 6.1.4.1.1. Research Laboratories, by Influenza A and B
        • 6.1.4.1.2. Research Laboratories, by COVID-19 Infections
        • 6.1.4.1.3. Research Laboratories, by Respiratory Syncytial Virus
        • 6.1.4.1.4. Research Laboratories, by Mycoplasma Infection
        • 6.1.4.1.5. Research Laboratories, by Pertussis
        • 6.1.4.1.6. Research Laboratories, by Other Respiratory Infections
      • 6.1.4.2. Research Laboratories Sexually Transmitted Infections (STIs) Market
        • 6.1.4.2.1. Research Laboratories, by Hepatitis B
        • 6.1.4.2.2. Research Laboratories, by HIV AIDS
        • 6.1.4.2.3. Research Laboratories, by HPV
        • 6.1.4.2.4. Research Laboratories, by Herpes Simplex Virus(HSV)
        • 6.1.4.2.5. Research Laboratories, by Neisseria gonorrhoeae
        • 6.1.4.2.6. Research Laboratories, by Other STIs
    • 6.1.5. Other End Users

7. Regions

  • 7.1. Overview
  • 7.2. North America
    • 7.2.1. North America Molecular Diagnostics Market (by Application)
      • 7.2.1.1. North America Respiratory Infections Molecular Diagnostics Market
        • 7.2.1.1.1. North America, by Influenza A and B
        • 7.2.1.1.2. North America, by COVID-19 Infections
        • 7.2.1.1.3. North America, by Respiratory Syncytial Virus
        • 7.2.1.1.4. North America, by Mycoplasma Infection
        • 7.2.1.1.5. North America, by Pertussis
        • 7.2.1.1.6. North America, by Other Respiratory Infections
      • 7.2.1.2. North America Sexually Transmitted Infections (STIs) Market
        • 7.2.1.2.1. North America, by Hepatitis B
        • 7.2.1.2.2. North America, by HIV AIDS
        • 7.2.1.2.3. North America, by HPV
        • 7.2.1.2.4. North America, by Herpes Simplex Virus(HSV)
        • 7.2.1.2.5. North America, by Neisseria gonorrhoeae
        • 7.2.1.2.6. North America, by Other STIs
    • 7.2.2. North America Molecular Diagnostics Market (by End User)
    • 7.2.3. U.S.
    • 7.2.4. Canada
  • 7.3. Europe
    • 7.3.1. Europe Molecular Diagnostics Market (by Application)
      • 7.3.1.1. Europe Respiratory Infections Molecular Diagnostics Market
        • 7.3.1.1.1. Europe, by Influenza A and B
        • 7.3.1.1.2. Europe , by COVID-19 Infections
        • 7.3.1.1.3. Europe, by Respiratory Syncytial Virus
        • 7.3.1.1.4. Europe, by Mycoplasma Infection
        • 7.3.1.1.5. Europe, by Pertussis
        • 7.3.1.1.6. Europe, by Other Respiratory Infections
      • 7.3.1.2. Europe Sexually Transmitted Infections (STIs) Market
        • 7.3.1.2.1. Europe, by Hepatitis B
        • 7.3.1.2.2. Europe, by HIV AIDS
        • 7.3.1.2.3. Europe, by HPV
        • 7.3.1.2.4. Europe, by Herpes Simplex Virus (HSV)
        • 7.3.1.2.5. Europe, by Neisseria gonorrhoeae
        • 7.3.1.2.6. Europe, by Other STIs
    • 7.3.2. Europe Molecular Diagnostics Market (by End User)
    • 7.3.3. Germany
    • 7.3.4. U.K.
    • 7.3.5. France
    • 7.3.6. Italy
    • 7.3.7. Spain
    • 7.3.8. Rest-of-Europe
  • 7.4. Asia-Pacific (APAC)
    • 7.4.1. Asia-Pacific Molecular Diagnostics Market (by Application)
      • 7.4.1.1. Asia-Pacific Respiratory Infections Molecular Diagnostics Market
        • 7.4.1.1.1. Asia-Pacific, by Influenza A and B
        • 7.4.1.1.2. Asia-Pacific , by COVID-19 Infections
        • 7.4.1.1.3. Asia-Pacific, by Respiratory Syncytial Virus
        • 7.4.1.1.4. Asia-Pacific, by Mycoplasma Infection
        • 7.4.1.1.5. Asia-Pacific, by Pertussis
        • 7.4.1.1.6. Asia-Pacific, by Other Respiratory Infections
      • 7.4.1.2. Asia-Pacific Sexually Transmitted Infections (STIs) Market
        • 7.4.1.2.1. Asia-Pacific, by Hepatitis B
        • 7.4.1.2.2. Asia-Pacific, by HIV AIDS
        • 7.4.1.2.3. Asia-Pacific, by HPV
        • 7.4.1.2.4. Asia-Pacific, by Herpes Simplex Virus (HSV)
        • 7.4.1.2.5. Asia-Pacific, by Neisseria gonorrhoeae
        • 7.4.1.2.6. Asia-Pacific, by Other STIs
    • 7.4.2. Asia-Pacific Molecular Diagnostics Market (by End User)
    • 7.4.3. China
    • 7.4.4. India
    • 7.4.5. Japan
    • 7.4.6. Australia
    • 7.4.7. Singapore
    • 7.4.8. Rest-of-Asia-Pacific
  • 7.5. Latin America (LATAM)
    • 7.5.1. Latin America Molecular Diagnostics Market (by Application)
      • 7.5.1.1. Latin America Respiratory Infections Molecular Diagnostics Market
        • 7.5.1.1.1. Latin America, by Influenza A and B
        • 7.5.1.1.2. Latin America, by COVID-19 Infections
        • 7.5.1.1.3. Latin America, by Respiratory Syncytial Virus
        • 7.5.1.1.4. Latin America, by Mycoplasma Infection
        • 7.5.1.1.5. Latin America, by Pertussis
        • 7.5.1.1.6. Latin America, by Other Respiratory Infections
      • 7.5.1.2. Latin America Sexually Transmitted Infections (STIs) Market
        • 7.5.1.2.1. Latin America, by Hepatitis B
        • 7.5.1.2.2. Latin America, by HIV AIDS
        • 7.5.1.2.3. Latin America, by HPV
        • 7.5.1.2.4. Latin America, by Herpes Simplex Virus (HSV)
        • 7.5.1.2.5. Latin America, by Neisseria gonorrhoeae
        • 7.5.1.2.6. Latin America, by Other STIs
    • 7.5.2. Latin America Molecular Diagnostics Market (by End User)
    • 7.5.3. Brazil
    • 7.5.4. Mexico
    • 7.5.5. Rest-of-Latin America
  • 7.6. Rest-of-the-World (RoW)
    • 7.6.1. Rest-of-the-World Molecular Diagnostics Market (by Application)
    • 7.6.2. Rest-of-the-World Molecular Diagnostics Market (by End User)
      • 7.6.2.1. Rest-of-the-World Respiratory Infections Molecular Diagnostics Market
      • 7.6.2.2. Rest-of-the-World Sexually Transmitted Infections (STIs) Market

8. Company Profiles

  • 8.1. Overview
  • 8.2. Abbott
    • 8.2.1. Company Overview
    • 8.2.2. Role of Abbott in the Global Molecular Diagnostics Market
    • 8.2.3. Financials
    • 8.2.4. Key Insights about Financial Health of the Company
    • 8.2.5. SWOT Analysis
  • 8.3. Agilent Technologies, Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Role of Agilent Technologies, Inc. in the Global Molecular Diagnostics Market
    • 8.3.3. Financials
    • 8.3.4. Key Insights about Financial of the Company
    • 8.3.5. SWOT Analysis
  • 8.4. Becton, Dickinson and Company (BD)
    • 8.4.1. Company Overview
    • 8.4.2. Role of Becton, Dickinson and Company (BD) in the Global Molecular Diagnostics Market
    • 8.4.3. Financials
    • 8.4.4. Key Insights about Financial Health of the Company
    • 8.4.5. SWOT Analysis
  • 8.5. bioMerieux SA
    • 8.5.1. Company Overview
    • 8.5.2. Role of bioMerieux SA in the Global Molecular Diagnostics Market
    • 8.5.3. Financials
    • 8.5.4. Key Insights about Financial Health of the Company
    • 8.5.5. SWOT Analysis
  • 8.6. Bio-Rad Laboratories, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Role of Bio-Rad Laboratories, Inc. in the Global Molecular Diagnostics Market
    • 8.6.3. Financials
    • 8.6.4. Key Insights about Financial Health of the Company
    • 8.6.5. SWOT Analysis
  • 8.7. Danaher
    • 8.7.1. Company Overview
    • 8.7.2. Role of Danaher in the Global Molecular Diagnostics Market
    • 8.7.3. Financials
    • 8.7.4. Key Insights about Financial Health of the Company
    • 8.7.5. SWOT Analysis
  • 8.8. F. Hoffmann-La Roche Ltd
    • 8.8.1. Company Overview
    • 8.8.2. Role of F. Hoffmann-La Roche Ltd in the Global Molecular Diagnostics Market
    • 8.8.3. Financials
    • 8.8.4. Key Insights about Financial Health of the Company
    • 8.8.5. SWOT Analysis
  • 8.9. Guardant Health
    • 8.9.1. Company Overview
    • 8.9.2. Role of Guardant Health in the Global Molecular Diagnostics Market
    • 8.9.3. Financials
    • 8.9.4. Key Insights about Financial Health of the Company
    • 8.9.5. SWOT Analysis
  • 8.1. HTG Molecular Diagnostics, Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Role of HTG Molecular Diagnostics, Inc. in the Global Molecular Diagnostics Market
    • 8.10.3. Financials
    • 8.10.4. Key Insights about Financial Health of the Company
    • 8.10.5. SWOT Analysis
  • 8.11. Illumina, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Role of Illumina, Inc. in the Global Molecular Diagnostics Market
    • 8.11.3. Financials
    • 8.11.4. Key Insights about Financial Health of the Company
    • 8.11.5. SWOT Analysis
  • 8.12. Invivoscribe, Inc.
    • 8.12.1. Company Overview
    • 8.12.2. Role of Invivoscribe, Inc. in the Global Molecular Diagnostics Market
    • 8.12.3. SWOT Analysis
  • 8.13. ICON plc
    • 8.13.1. Company Overview
    • 8.13.2. Role of ICON plc in the Global Molecular Diagnostics Market
    • 8.13.3. SWOT Analysis
  • 8.14. LungLife AI, Inc.
    • 8.14.1. Company Overview
    • 8.14.2. Role of LungLife AI, Inc. in the Global Molecular Diagnostics Market
    • 8.14.3. SWOT Analysis
  • 8.15. QIAGEN
    • 8.15.1. Company Overview
    • 8.15.2. Role of QIAGEN in the Global Molecular Diagnostics Market
    • 8.15.3. Financials
    • 8.15.4. Key Insights about Financial Health of the Company
    • 8.15.5. SWOT Analysis
  • 8.16. QuantuMDx Group Ltd.
    • 8.16.1. Company Overview
    • 8.16.2. Role of QuantuMDx Group Ltd. in the Global Molecular Diagnostics Market
    • 8.16.3. SWOT Analysis
  • 8.17. Siemens Healthcare GmbH
    • 8.17.1. Company Overview
    • 8.17.2. Role of Siemens Healthcare GmbH in the Global Molecular Diagnostics Market
    • 8.17.3. Financials
    • 8.17.4. Key Insights about Financial Health of the Company
    • 8.17.5. SWOT Analysis
  • 8.18. Thermo Fisher Scientific Inc.
    • 8.18.1. Company Overview
    • 8.18.2. Role of Thermo Fisher Scientific Inc. in the Global Molecular Diagnostics Market
    • 8.18.3. Financials
    • 8.18.4. Key Insights About Financial Health of the Company
    • 8.18.5. SWOT Analysis